步長製藥(603858.SH):浙江天元與相關實驗室合作研發新冠病毒疫苗項目
格隆匯2月12日丨步長製藥(603858.SH)公佈,之前公告披露,公司出資人民幣6112.36萬元對南京華派生物醫藥有限公司(“南京華派”)進行增資,增資完成後,佔南京華派註冊資本的比例為54.4%。浙江天元生物藥業有限公司(“浙江天元”)為南京華派的全資子公司。
浙江天元於2020年2月12日與傳染病診治國家重點實驗室(浙江大學)(“實驗室”)簽署了《新型冠狀病毒疫苗合作框架協議》,為積極應對我國當前新型冠狀病毒肺炎疫情,加快疫苗研發,雙方共同合作研發新型冠狀病毒疫苗項目。
雙方一旦簽訂合作協議,雙方不得將該疫苗株及相關知識產權向任何第三方轉讓;若因疫情防控需要,甲乙雙方一致同意將相關研究成果貢獻給國家。
此次浙江天元與實驗室簽訂《合作框架協議》,不會對公司及浙江天元財務狀況和經營成果產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.